<SEC-DOCUMENT>0001193125-21-208953.txt : 20210707
<SEC-HEADER>0001193125-21-208953.hdr.sgml : 20210707
<ACCEPTANCE-DATETIME>20210706193159
ACCESSION NUMBER:		0001193125-21-208953
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210706
FILED AS OF DATE:		20210707
DATE AS OF CHANGE:		20210706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		211075820

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d183416d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July&nbsp;6, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d183416dex991.htm">Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July&nbsp;6, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d183416dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g183416g25h59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep receives FDA and IRB approval in the US for Phase IIb <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial in HNSCC </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regulatory steps completed with the competent authority (FDA) and institutional review board (IRB) approval
received in the United States to commence <FONT STYLE="white-space:nowrap">TACTI-003</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patient recruitment into the trial is expected to begin within this quarter with European and Australian sites
expected to follow </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 6 </B><B>July</B><B> 2021 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy treatments for cancer and autoimmune disease, announces it has completed all the necessary
competent authority steps with the US Food and Drug Administration (FDA) and has received IRB approval to commence its phase IIb <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial in the United States. Patient recruitment for the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> trial is expected to begin within this quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-003</FONT> will
evaluate the Company&#146;s lead product candidate, eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), in combination with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) as a first line therapy
in approximately 154 patients with Head and Neck Squamous Cell Carcinoma (HNSCC). It is a randomised, controlled clinical study that will take place across Australia, Europe and the United States of America in up to 35 clinical sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending approval by the European and Australian competent authorities and ethics committees, Immutep expects to broaden its recruitment sites into these
regions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commenting on the start of the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial, </B><B>Immutep</B><B> CSO and CMO
</B><B>Fr</B><B>&eacute;</B><B>d</B><B>&eacute;</B><B>ric</B><B> </B><B>Triebe</B><B>l</B><B> said:</B> &#147;We are delighted to start our new <FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial in
1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab monotherapy. Results we reported from this therapeutic combination earlier in June at ASCO in the 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> line setting were robust, with sustained and durable responses. We look forward to deepening these results with a larger group of 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line HNSCC
patients in <FONT STYLE="white-space:nowrap">TACTI-003.&#148;</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-003</FONT> is a Phase IIb clinical trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC). It will evaluate
efti in combination with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) as a first line therapy in unresectable recurrent or metastatic HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT>
negative and <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1) tumors. It will be a randomised, controlled clinical study in approximately 154 first line HNSCC patients and will take place
across Australia, Europe and the United States of America in up to 35 clinical sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited,</B>
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g183416g25h59.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study will evaluate the safety and efficacy of efti in combination with pembrolizumab, compared to
pembrolizumab alone in 1st line metastatic or recurrent HNSCC patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1) tumors (cohort A), and determine the efficacy and safety of efti
plus pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumors (CPS &lt;1) (cohort B). According to the current plans, about 130 patients in cohort A will be randomised 1:1 to receive either efti plus pembrolizumab
or pembrolizumab alone. Subjects in cohort B (up to 24 patients) will receive a combination of efti and pembrolizumab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study
is the Overall Response Rate (ORR) according to RECIST 1.1. and iRECIST will be used for treatment decisions. Secondary endpoints include OS and Progression Free Survival (PFS). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be
found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited,
</B>Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g183416g25h59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g183416g25h59.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&
M!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8#
M P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# S_P  1" !J R # 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M=PSV$=M?6*.?EG5EVK*.Y!Q@ ]\ @'Z;^:H([%N@-'G+^=>1_M>?'#4/@_\
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M;*RQ_,,?C4E%%>@?2A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ4EYGT6=_P ;!O\ O?H?6/[=&F1W7[+'BQI8XY'AMTFB8KDQR"1<,/2O'O\
M@E!*YL?&T6YA#'-;2!/0LLBD_DBC\*]L_;=PG[+GB[)4;K-1D]!\ZUX?_P $
MHWS'XZ*XWJ]G@=<$K-SQV.:*W^^P]&/&1MGE!KK!GR;=-M_X*[6N>K?$6W!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRV^=I8[N3GN?6I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT.S\F>/[+;[;K<9E\L8E+<-N'?/?/6K5% %6/2+6VN&F2WA6>1!&9 @#,HZ
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M&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4
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M_BJ_3[RU_NK^5'EK_=7\J/[%I?S/[P_U-I?\_I_>?F#_ ,,D?%/_ *$W7O\
MQW_XJC_ADCXI_P#0FZ]_X[_\57Z?>6O]U?RH\M?[J_E1_8M+^9_>'^IM+_G]
M/[S\P?\ ADCXJ?\ 0FZ]_P"._P#Q5'_#)'Q3_P"A-U[_ ,=_^*K]/O+7^ZOY
M4>6O]U?RH_L6G_,P_P!3:/\ S^E]Y^8/_#)'Q3_Z$W7O_'?_ (JC_ADCXI_]
M";KW_CO_ ,57Z?>6O]U?RH\M?[J_E1_8M+^9_>'^IM+_ )_3^\_,'_ADCXI_
M]";KW_CO_P 51_PR1\4_^A-U[_QW_P"*K]/O+7^ZOY4>6O\ =7\J/[%I?S/[
MP_U-I?\ /Z?WGY@_\,D?%/\ Z$W7O_'?_BJ/^&2/BG_T)NO?^.__ !5?I]Y:
M_P!U?RH\M?[J_E1_8M+^9_>'^IM+_G]/[S\P?^&2/BG_ -";KW_CO_Q5'_#)
M'Q4_Z$W7O_'?_BJ_3[RU_NK^5'EK_=7\J/[%I?S/[P_U-I?\_I_>?F#_ ,,D
M_%3_ *$S7_\ QW_XJE/[(_Q4'_,FZ]_X[_\ %5^GPC7/W5_*@1K_ '5_*A9+
M3_F8O]3:/_/Z7WGY@#]DCXJ'_F3=?_\ '?\ XJC_ (9(^*?_ $)NO?\ CO\
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MFZ]_X[_\57Z?>6O]U?RH\M?[J_E1_8M+^9_>'^IM+_G]/[S\P?\ ADCXI_\
M0FZ]_P"._P#Q5'_#)'Q3_P"A-U[_ ,=_^*K]/O+7^ZOY4>6O]U?RH_L6E_,_
MO#_4VC_S^E]Y^8/_  R1\5/^A-U[_P =_P#BJ/\ ADCXI_\ 0FZ]_P"._P#Q
M5?I]Y:_W5_*CRU_NK^5']BTOYG]X?ZFT?^?TOO/S!_X9(^*?_0FZ]_X[_P#%
M4?\ #)'Q3_Z$W7O_ !W_ .*K]/O+7^ZOY4>6O]U?RH_L6E_,_O#_ %-I?\_I
M_>?F#_PR1\4_^A-U[_QW_P"*H_X9(^*?_0FZ]_X[_P#%5^GWEK_=7\J/+7^Z
MOY4?V+2_F?WA_J;2_P"?T_O/S!_X9(^*?_0FZ]_X[_\ %4?\,D?%/_H3=>_\
M=_\ BJ_3[RU_NK^5'EK_ '5_*C^Q:7\S^\/]3:7_ #^G]Y^8/_#)'Q3_ .A-
MU[_QW_XJC_ADCXI_]";KW_CO_P 57Z?>6O\ =7\J/+7^ZOY4?V+2_F?WA_J;
M2_Y_3^\_,'_ADCXI_P#0FZ]_X[_\51_PR1\4_P#H3=>_\=_^*K]/O+7^ZOY4
M>6O]U?RH_L6E_,_O#_4VE_S^G]Y^8/\ PR1\4_\ H3=>_P#'?_BJ/^&2/BG_
M -";KW_CO_Q5?I]Y:_W5_*CRU_NK^5']BTOYG]X?ZFTO^?T_O/S!_P"&2/BG
M_P!";KW_ ([_ /%4?\,D?%3_ *$W7O\ QW_XJOT^\M?[J_E2B-<_=7\J/[%I
M?S/[P_U-I?\ /Z?WGY@_\,C_ !4_Z$W7O_'?_BJ3_ADCXJ?]";KW_CO_ ,57
MZ?\ EKC[J_E2>6O]U?RH_L6G_,P_U-H_\_I?>?F#_P ,D?%/_H3=>_\ '?\
MXJC_ (9(^*?_ $)NO?\ CO\ \57Z?>6O]U?RH\M?[J_E1_8M+^9_>'^IM+_G
M]/[S\PO^&1_BI_T)NO?^._\ Q5)_PR1\5/\ H3=>_P#'?_BJ_3_RUQ]U?RH,
M:_W5_*C^Q:7\S^\/]3:7_/Z?WGY@?\,D?%/_ *$W7O\ QW_XJC_ADCXI_P#0
MFZ]_X[_\57Z?>6O]U?RH\M?[J_E1_8M+^9_>'^IM+_G]/[S\P?\ ADCXI_\
M0FZ]_P"._P#Q5'_#)'Q2_P"A-U[_ ,=_^*K]/Q&N?NK^5+Y:[_NK^5']BT_Y
+F2^#Z*?\67WG_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
